Azithromycin reduces exaggerated cytokine production by M1 alveolar macrophages in cystic fibrosis. - Wikidata - wikimedia - TriplyDB

Azithromycin reduces exaggerated cytokine production by M1 alveolar macrophages in cystic fibrosis.

Azithromycin reduces exaggerated cytokine production by M1 alveolar macrophages in cystic fibrosis.

http://www.wikidata.org/entity/Q46108631

about

Cystic fibrosis therapeutics: the road ahead Azithromycin drives alternative macrophage activation and improves recovery and tissue sparing in contusion spinal cord injury Inflammasome-mediated IL-1β production in humans with cystic fibrosis Mechanisms of action and clinical application of macrolides as immunomodulatory medications.Macrophages: plastic solutions to environmental heterogeneity.Tacrolimus (FK506) suppresses TREM-1 expression at an early but not at a late stage in a murine model of fungal keratitis Impact of MIF gene promoter polymorphism on F508del cystic fibrosis patients Dysregulated proinflammatory and fibrogenic phenotype of fibroblasts in cystic fibrosis The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction.Efficacy of combination therapy with oseltamivir phosphate and azithromycin for influenza: a multicenter, open-label, randomized study Impact of azithromycin treatment on macrophage gene expression in subjects with cystic fibrosis.Role of IL-1β in experimental cystic fibrosis upon P. aeruginosa infection.Pathogen- and host-directed anti-inflammatory activities of macrolide antibiotics Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.Mycobacterium leprae alters classical activation of human monocytes in vitro.Effect of azithromycin on systemic markers of inflammation in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa.Reduced caveolin-1 promotes hyperinflammation due to abnormal heme oxygenase-1 localization in lipopolysaccharide-challenged macrophages with dysfunctional cystic fibrosis transmembrane conductance regulator.Azithromycin Attenuates Pseudomonas-Induced Lung Inflammation by Targeting Bacterial Proteins Secreted in the Cultured Medium.Role of IRE1α/XBP-1 in Cystic Fibrosis Airway Inflammation.Impaired defenses of neonatal mouse alveolar macrophage with cftr deletion are modulated by glutathione and TGFβ1 Long-term macrolide treatment of chronic inflammatory airway diseases: risks, benefits and future developments.IL-17A in human respiratory diseases: innate or adaptive immunity? Clinical implications.Antibacterial and immunomodulatory properties of azithromycin treatment implications for periodontitis.Azithromycin analogue CSY0073 attenuates lung inflammation induced by LPS challenge.Inflammation and its genesis in cystic fibrosis.Cystic Fibrosis Lung Immunity: The Role of the Macrophage Azithromycin suppresses interleukin-12p40 expression in lipopolysaccharide and interferon-gamma stimulated macrophages.Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas.PDE5 Inhibitors as Potential Tools in the Treatment of Cystic Fibrosis.Neutrophil extracellular traps and the dysfunctional innate immune response of cystic fibrosis lung disease: a review.CFTR-dependent chloride efflux in cystic fibrosis mononuclear cells is increased by ivacaftor therapy.Correction of lung inflammation in a F508del CFTR murine cystic fibrosis model by the sphingosine-1-phosphate lyase inhibitor LX2931.The anti-inflammatory mechanism of heme oxygenase-1 induced by hemin in primary rat alveolar macrophages.Concentration-dependent effects of antimicrobials on Staphylococcus aureus toxin-mediated cytokine production from peripheral blood mononuclear cells.Long-term dietary (n-3) polyunsaturated fatty acids show benefits to the lungs of Cftr F508del mice.Azithromycin promotes alternatively activated macrophage phenotype in systematic lupus erythematosus via PI3K/Akt signaling pathway

P2860

Q27022401-C3C7672C-82D6-48AF-9C6E-2585F624266B Q27303481-F2029F71-918B-49BC-B450-A0A8B55157D1 Q28483902-11DC0F87-6C56-4087-A8D6-4C0B9268FCF5 Q33983140-480712BB-3E0A-4925-AE28-823D98EAF477 Q34358862-ED8F1CCF-2A9F-4616-878D-0B1F2AE76AAE Q34612464-1FDFE6FC-A534-473E-ADCE-F702B20882AC Q34689530-11AB41D1-5C0F-4226-B605-EC1094F8C891 Q34755463-C1678110-1E97-499C-9D84-7AECF8C4037D Q34769319-F940DE28-8AE7-4391-BF7A-2B3DFFF334A6 Q35121720-B5E55719-CA7A-44A2-9E14-D475E0526524 Q35223657-43F7C5BF-3DE8-479B-8EA3-D60A2D5C0ED2 Q35513939-F56027C5-7FE5-4A20-89E0-B90F9B2E9521 Q36072425-F738405D-91B6-4B47-A5BA-CB61DDC666FA Q36675133-6A17B1AB-5655-4B53-B9D3-1D9AC132627D Q36679019-15DED14F-B732-4736-8CDF-983EBADFE40F Q36723908-5780C875-D083-4FEE-AF70-C08127AED0FB Q37011814-0F2FD753-6531-407A-ADAA-AC1D219B743A Q37413404-C609D55C-3673-46B4-9B35-4FA65F47B1F5 Q37631563-81D610A6-C1F0-4D9A-ACFC-5A79371193C2 Q37727368-69554D35-F1AF-485B-AAB6-211790F14D8F Q38038317-B8D7BAED-EA73-4EAC-8433-5457A800D013 Q38080843-DEE9F63B-6431-44DC-AF5B-F94F59A760FF Q38085248-470DAD9D-8C07-424A-B0D1-35A8EF779201 Q38529613-C5E5FFA6-C58A-4642-A82A-40075B56BF1E Q38579962-2D30E72A-8ACC-4E41-8266-7A2971E89C5B Q38874414-D64892C3-85E9-455F-92D3-451751D994EB Q39778460-A2609AE5-DB3D-4CC1-9E8B-09D6E1E9DD78 Q40749683-45338B97-3885-45DF-8877-B8EFFF73FCB9 Q42325938-3427A732-0C85-43B1-A785-BDEAFBC4C5A2 Q47183658-E0ADC371-9B29-4228-80F1-21AF9B8B2309 Q47909858-58EE6DFB-1F4C-4077-8C53-C42471982CCF Q48678102-96EDFEE2-5FD0-470B-8015-30CCE559D724 Q50520907-411D432A-A7F3-4202-986F-56D9A3993CE0 Q51002414-FD9377BB-DA4C-455B-840F-B87774B0EC5C Q55104275-E0FDB36F-7C48-433A-823C-E85E5E59C2D9 Q57801756-875464D2-E060-4C76-A244-7CC0BF589827

P2860

Azithromycin reduces exaggerated cytokine production by M1 alveolar macrophages in cystic fibrosis.

http://www.wikidata.org/entity/Q46108631

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Azithromycin reduces exaggerat ...... acrophages in cystic fibrosis.

@en

Azithromycin reduces exaggerat ...... acrophages in cystic fibrosis.

@nl

type

label

Azithromycin reduces exaggerat ...... acrophages in cystic fibrosis.

@en

Azithromycin reduces exaggerat ...... acrophages in cystic fibrosis.

@nl

prefLabel

Azithromycin reduces exaggerat ...... acrophages in cystic fibrosis.

@en

Azithromycin reduces exaggerat ...... acrophages in cystic fibrosis.

@nl

P1433

Q46108631-673E0CC2-8C3D-4F08-94AE-2A26A020A10D

P1476

Q46108631-C79B6C5B-9A44-4F1C-A719-276188FF0704

P2093

Q46108631-1A5BB6BB-431D-4835-AD18-88465C32A2B3

Q46108631-32CACDDF-D807-4C48-844E-B487A2E55B1C

Q46108631-4D7F1574-5939-4EDD-9E40-B2F6C5E653E8

Q46108631-506B3A65-62A7-42F6-9733-562EE49C69ED

Q46108631-686CE0FA-E290-4B08-A145-BE665A8B56D8

Q46108631-91FAFBC5-06D6-4C4D-B317-72FCB76E2567

Q46108631-AB4DE14C-E1F0-4C60-A75E-7142C9BBCFAE

Q46108631-CA999384-D938-478E-AD09-9AB648B5903F

Q46108631-DCEC7446-C5B9-44FF-9D43-996C2E49CD49

P2860

Q46108631-08A75A5C-66FA-443D-A25B-B3D70FAF536D

Q46108631-1165A765-0C77-421A-AF43-C179412EB308

Q46108631-21547E91-736D-4DCE-B442-3AEE9E932DD9

Q46108631-2D146914-CB62-4167-88D7-F1AD1C96AC52

Q46108631-37BC2AA6-575B-4568-8E11-E0776FA07600

Q46108631-39A41FE9-E052-44EF-A4F8-CB1B2B179509

Q46108631-4A57B8CE-A659-4CA6-81EE-9654FBE6497E

Q46108631-53F9861D-A888-45D6-B313-B056EEAECC47

Q46108631-6032F772-04D0-4019-8AAD-8BABE4BE7203

Q46108631-658BDF1C-C020-4606-AC29-AD448DBF0F90

P304

Q46108631-0255904C-7082-4F7F-9F21-E8CCF677EFD9

P31

Q46108631-FA0DF8F3-A084-4888-99C9-975026C430BC

P356

Q46108631-D12F5B4D-10E9-4DC4-B673-8A78255B7C2B

P433

Q46108631-4A731396-7238-4D4F-B640-366D9582D65C

P478

Q46108631-A2C28771-C6B8-45A6-91C4-978343A69D97

P50

Q46108631-5527957D-B7C7-4854-AD0C-8E8B6911E17F

P577

Q46108631-3C53C0DE-70B0-4A7B-A075-F83EFBFDE68F

P698

Q46108631-0481B3BF-C00E-49C6-BBBB-569F85F17E4E

P921

Q46108631-53B87E08-69BA-4392-B2F6-FDA8242D4CE5

Q46108631-A9D393E8-A2DD-437B-83A7-0E3B6FC677DD

P356

RCMB.2008-0155OC

P1433

American Journal of Respiratory Cell and Molecular Biology

P1476

Azithromycin reduces exaggerat ...... acrophages in cystic fibrosis.

@en

P2093

Bob Scholte

http://www.w3.org/2001/XMLSchema#string

François Huaux

http://www.w3.org/2001/XMLSchema#string

Magali Meyer

http://www.w3.org/2001/XMLSchema#string

Patrick Lebecque

http://www.w3.org/2001/XMLSchema#string

Pierre Wallemacq

http://www.w3.org/2001/XMLSchema#string

Sandra Lo Re

http://www.w3.org/2001/XMLSchema#string

Sybille van den Brûle

http://www.w3.org/2001/XMLSchema#string

Teresinha Leal

http://www.w3.org/2001/XMLSchema#string

Ximena Gavilanes

http://www.w3.org/2001/XMLSchema#string

P2860

Monocyte and macrophage heterogeneity

The chemokine system in diverse forms of macrophage activation and polarization

Significant involvement of CCL2 (MCP-1) in inflammatory disorders of the lung.

Classical and alternative activation of mononuclear phagocytes: picking the best of both worlds for tumor promotion.

Azithromycin reduces spontaneous and induced inflammation in DeltaF508 cystic fibrosis mice.

Regulation of chemokine expression by NaCl occurs independently of cystic fibrosis transmembrane conductance regulator in macrophages.

Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial.

Selective up-regulation of chemokine IL-8 expression in cystic fibrosis bronchial gland cells in vivo and in vitro

Expression of the cystic fibrosis transmembrane conductance regulator gene in cells of non-epithelial origin.

Long term effects of azithromycin in patients with cystic fibrosis: A double blind, placebo controlled trial.

P304

590-602

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1165/RCMB.2008-0155OC

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

41

http://www.w3.org/2001/XMLSchema#string

P50

Dominique Lison

P577

2009-02-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19244203

http://www.w3.org/2001/XMLSchema#string

P921

cystic fibrosis